Canine Melanoma Combination

About HylaPharm

HylaPharm is a private, preclinical-stage biotech leveraging a proprietary hyaluronan-based nanoconjugate platform for localized drug delivery. The company's lead programs focus on intratumoral delivery of chemotherapeutics (like cisplatin) and immunomodulators to stimulate anti-tumor immunity, with compelling proof-of-concept data from spontaneous canine cancer models. Its dual strategy targets the significant unmet need in human immuno-oncology, where many patients are resistant to checkpoint inhibitors, while also addressing the veterinary oncology market. The company has been funded through SBIR grants and angel investment.

Therapeutic Areas

Other Canine Melanoma Drugs